Adherence to Treatment and Prevention Program

Overview

This program supports scientific research on initiation and adherence to biomedical HIV prevention methods [e.g., pre-exposure prophylaxis (PrEP)] and antiretroviral therapy for HIV treatment. Within these domains, the program supports studies to inform future interventions, to develop and test novel interventions, and to advance the dissemination and implementation of proven interventions. Intervention research may target individuals, providers, or healthcare systems and policies. The program invites research conducted in U.S. domestic settings or international settings that have high HIV incidence or prevalence, with an emphasis on approaches likely to have broad impact.

Areas of Emphasis

• Understand, promote, and support uptake of and adherence to biomedical HIV prevention approaches (e.g., PrEP, microbicides) among those who may benefit, to maximize their effectiveness and impact.
• Advance adherence assessment and monitoring, and to incorporate such measures into routine care to improve the identification of individuals in need of adherence support
• Improve HIV treatment outcomes through the development and testing of interventions that will improve and sustain antiretroviral adherence. Adherence intervention trials should assess impact on both behavioral adherence and biological outcomes such as viral suppression.
• Understand and address provider, clinic, and systems-level factors that may impact antiretroviral initiation and adherence for HIV prevention and treatment.
• Develop and test targeted interventions designed to reduce documented racial/ethnic, gender, and age-related disparities in HIV PrEP and antiretroviral therapy use and outcomes.

Contact

Michael J. Stirratt, Ph.D.
5601 Fishers Lane, Room 9G28
Rockville, MD 20852
240-627-3875, stirrattm@mail.nih.gov